Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Anti‐GD2 Antibody‐containing Immunotherapy Postconsolidation Therapy for People With High‐risk Neuroblastoma Treated With Autologous Haematopoietic Stem Cell Transplantation." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation. Accessed 21 September 2023.
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation. Accessed September 21, 2023.
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation
Anti‐GD2 Antibody‐containing Immunotherapy Postconsolidation Therapy for People With High‐risk Neuroblastoma Treated With Autologous Haematopoietic Stem Cell Transplantation [Internet]. In: Cochrane Abstracts. [cited 2023 September 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
ID - 434652
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation
DB - Evidence Central
DP - Unbound Medicine
ER -